FENNEC PHARMACEUTICALS INC. (FENC) SEC Filings & Earnings Calls
EquiReason read 7 FENNEC PHARMACEUTICALS INC. SEC filings in the last 12 months. Latest: 8-K on 2026-09-17 — Fennec Pharmaceuticals announces positive Phase 2 STS-J01 study results for PEDMARK in Japan; met primary endpoint with significant hearing protection and no interference with cisp.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 353.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
13 Aug 202610-QFennec Pharmaceuticals reported strong Q2 2026 results with revenue up 85% YoY to $17.9M and achieved first profitable quarter with net income of $2.0M, driven by PEDMARK market penetration and AYA expansion.earningsopen
Figures in the filing · each found in the filing text
| PEDMARK product sales, net · Q2-2026 | $17M | +78% y/y |
| Total revenue · Q2-2026 | $18M | +85% y/y |
| Net income/(loss) · Q2-2026 | $2M | |
| Adjusted EBITDA · Q2-2026 | $3M | |
| Cash and cash equivalents · 2026-06-30 | $41M | |
| Operating cash flow · H1-2026 | $2M | |
| Gross margin % · Q2-2026 | 96.0% |
Risks flagged
Commercial execution risk
“Selling and marketing expenses increased 123% YoY to $10.7M in Q2 2026, outpacing revenue growth of 85%.”
Concentration risk
“For the three and six months ended June 30, 2026, the Company had two distributors that each represented more than 10% of net sales.” · word for word
Patent litigation risk
“Cipla settlement provides exclusivity until 2033, but generic entry could occur earlier under certain circumstances.”
14 May 202610-QCompany reported net income of $201k in Q1 2026 vs net loss of $1,165k in Q1 2025, and settled Cipla patent litigation delaying generic competition until 2033earningsopen
Figures in the filing · each found in the filing text
| Net income/(loss) · Q1-2026 | $201000.00 | |
| Cash and cash equivalents · 2026-03-31 | $40M |
Risks flagged
Generic competition risk reduced by settlement
“CIPLA will not enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033” · word for word
Concentration on single product PEDMARK
“The Company operates as a single operating and reportable segment focused on the commercialization of PEDMARK®/PEDMARQSI®” · word for word
28 Apr 2026DEF 14AProxy statement for annual meeting; includes proposals to increase equity plan shares and adopt a new inducement plan.open
Figures in the filing · each found in the filing text
| Net income · FY2025 | $-10M |
Risks flagged
Net loss and negative equity
“Net Income (millions) 2025: (9,741); 2024: (436); 2023: (16,045)”
27 Mar 202610-KFennec reported FY2025 results: net loss of $9.7M, cash of $36.8M, and highlighted sequential revenue growth and positive operating cash flow in Q3 2025.earningsopen
Figures in the filing · each found in the filing text
| Net loss · FY2025 | $-10M | |
| Cash and cash equivalents · 2025-12-31 | $37M | |
| Accumulated deficit · 2025-12-31 | $229M | |
| Research and development expenses · FY2025 | $250000.00 | |
| Number of employees · 2025-12-31 | 35 |
Risks flagged
Single product dependency
“PEDMARK ® is currently our only product and there is no assurance that we will successfully develop PEDMARK ® into a commercially viable product.” · word for word
History of losses
“We have incurred significant operating losses every year since our inception in September 1996.” · word for word
Generic competition risk
“compounded sodium thiosulfate is likely to be substantially less expensive than PEDMARK ® .” · word for word
Patent litigation risk
“We may be forced to defend claims of infringement brought by our competitors and others, and we may institute litigation against others who we believe are infringing our intellectual property rights.” · word for word
Reimbursement risk
“Coverage and reimbursement may be limited or unavailable in certain market segments for our product, which could make it difficult for us to sell our product profitably.” · word for word
24 Mar 20268-K · 2.02Record annual net product sales of $44.6M (+50% YoY); Q4 net product sales $13.8M (+75% YoY); positive topline results from Japan trial; oversubscribed $42M equity offering; debt redemption completed.earningsopen
Figures in the filing · each found in the filing text
| Net Product Sales · FY2025 | $45M | +50% y/y |
| Net Product Sales · Q4-2025 | $14M | +75% y/y |
| Selling and Marketing Expenses · Q4-2025 | $6M | +56% y/y |
Risks flagged
Dependence on single product PEDMARK for revenue; any setback in adoption or competition could impact growth.
“Revenue entirely from PEDMARK; no other products mentioned.”
Increased selling and marketing expenses may pressure margins if revenue growth decelerates.
“Selling and marketing expenses increased to $6.1M in Q4 2025 from $3.9M in Q4 2024.”
13 Nov 202510-QFennec Pharmaceuticals reported a net loss of $0.6M for Q3 2025, improved from a loss of $5.7M in Q3 2024, with no material changes in accounting policies or business operations.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $-638000.00 | |
| Net loss · 9M-2025 | $-5M | |
| Cash and cash equivalents · 2025-09-30 | $22M | |
| Allowance for credit losses · 2025-09-30 | $3845.00 | |
| Capitalized inventory · 2025-09-30 | $2M | |
| Stock-based compensation expense · Q3-2025 | $2M | |
| Stock-based compensation expense · 9M-2025 | $5M | |
| Term loan outstanding · 2025-09-30 | $19M | |
| Capitalized incremental costs (Norgine) · 2025-09-30 | $743000.00 |
Risks flagged
CIPLA patent litigation
“On August 25, 2025, the CIPLA entities filed an Answer and Counterclaims to the complaint, alleging that the '026 Patent was invalid, not infringed, and/or unenforceable.” · word for word
Concentration of credit risk
“In the U.S., the customers are a limited group of specialty distributors, and direct customers, and accordingly, the Company considers the risk of potential credit losses to be low.” · word for word
Full valuation allowance on deferred tax assets
“As of September 30, 2025, we maintained a full valuation allowance against our deferred tax assets.” · word for word
FENNEC PHARMACEUTICALS INC. — questions
- What did FENNEC PHARMACEUTICALS INC. file recently?
- 7 SEC filings in the last 12 months. Latest: 8-K on 2026-09-17 — Fennec Pharmaceuticals announces positive Phase 2 STS-J01 study results for PEDMARK in Japan; met primary endpoint with significant hearing protection and no interference with cisplatin antitumor activity.
Every figure on this page comes from FENNEC PHARMACEUTICALS INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.